- |||||||||| ADXS-NEO / Ayala Pharma
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of ADXS-NEO Expressing Personalized Tumor Antigens (clinicaltrials.gov) - Aug 11, 2020
P1, N=5, Active, not recruiting,
Unknown status --> Terminated; Business decision Trial completion date: May 2020 --> Jan 2022 | Trial primary completion date: May 2020 --> Jan 2022
- |||||||||| ADXS-NEO / Ayala Pharma
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of ADXS-NEO Expressing Personalized Tumor Antigens (clinicaltrials.gov) - Jan 13, 2020
P1, N=5, Active, not recruiting,
Trial completion date: May 2020 --> Jan 2022 | Trial primary completion date: May 2020 --> Jan 2022 Recruiting --> Active, not recruiting | N=48 --> 5 | Trial completion date: Sep 2020 --> May 2020 | Trial primary completion date: Sep 2019 --> May 2020
- |||||||||| ADXS-NEO / Ayala Pharma
Trial initiation date, Combination therapy, Metastases: A Study of ADXS-NEO Expressing Personalized Tumor Antigens (clinicaltrials.gov) - Jan 10, 2019
P1, N=48, Recruiting,
Enrollment in a combination therapy arm with pembrolizumab is due to start in 4Q2019. Initiation date: Mar 2018 --> Jun 2018
- |||||||||| ADXS-NEO / Ayala Pharma
Enrollment open, Trial initiation date, Combination therapy, Metastases: A Study of ADXS-NEO Expressing Personalized Tumor Antigens (clinicaltrials.gov) - Mar 15, 2018
P1, N=48, Recruiting,
Initiation date: Mar 2018 --> Jun 2018 Not yet recruiting --> Recruiting | Initiation date: Sep 2017 --> Mar 2018
|
